
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Recall from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/recall/topic/15576/</link>
        <description>Articles tagged with Recall from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Business Briefs: GSK, Astellas, Vertex and Orexigen</title>
          <description>GSK and Astellas kick off the race for a new anemia treatment; Orexigen&apos;s CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.</description>
          <link>http://www.mmm-online.com/business-briefs-gsk-astellas-vertex-and-orexigen/article/289879/</link>
          <pubDate>Mon, 22 Apr 2013 16:19:10 GMT</pubDate>
          <itunes:summary>GSK and Astellas kick off the race for a new anemia treatment; Orexigen&apos;s CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Business briefs: Élan, Teva</title>
          <description>A buyout offer upsets Elan&apos;s post-Tysabri plans, Takeda and Affymax recall Omontys.</description>
          <link>http://www.mmm-online.com/business-briefs-élan-teva/article/281800/</link>
          <pubDate>Mon, 25 Feb 2013 17:41:45 GMT</pubDate>
          <itunes:summary>A buyout offer upsets Elan&apos;s post-Tysabri plans, Takeda and Affymax recall Omontys.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>J&amp;J OTC sales slipped 3% in 2012 worldwide</title>
          <description>CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year&apos;s numbers.</description>
          <link>http://www.mmm-online.com/jj-otc-sales-slipped-3-in-2012-worldwide/article/277043/</link>
          <pubDate>Tue, 22 Jan 2013 18:19:42 GMT</pubDate>
          <itunes:summary>CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year&apos;s numbers.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>J&amp;J says no shakeup at McNeil Consumer Healthcare unit</title>
          <description>J&amp;J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.</description>
          <link>http://www.mmm-online.com/jj-says-no-shakeup-at-mcneil-consumer-healthcare-unit/article/225876/</link>
          <pubDate>Wed, 01 Feb 2012 21:03:58 GMT</pubDate>
          <itunes:summary>J&amp;J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  